Free Trial

Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down - Here's What Happened

Hypermarcas logo with Medical background

Key Points

  • Hypermarcas shares gapped down to $4.41 at the start of trading, down from a previous close of $4.64, with a trading volume of 469 shares.
  • Scotiabank has upgraded Hypermarcas to a "strong-buy" rating, contributing to an average rating of "Strong Buy" among analysts.
  • The company recently declared a dividend of $0.0345, which represents an impressive yield of 281.0%, set to be paid on January 8th.
  • MarketBeat previews top five stocks to own in November.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $4.64, but opened at $4.41. Hypermarcas shares last traded at $4.41, with a volume of 469 shares.

Wall Street Analysts Forecast Growth

Separately, Scotiabank upgraded Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, Hypermarcas currently has an average rating of "Strong Buy".

Check Out Our Latest Report on HYPMY

Hypermarcas Stock Down 3.0%

The firm has a market cap of $2.78 billion, a PE ratio of 20.91 and a beta of 0.86. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The firm's 50 day moving average is $4.45 and its 200-day moving average is $4.20.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

About Hypermarcas

(Get Free Report)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Read More

Should You Invest $1,000 in Hypermarcas Right Now?

Before you consider Hypermarcas, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.

While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.